Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UCB Group

www.ucb-group.com

Latest From UCB Group

Argenx Builds Presence As Efgartigimod Positive In Pivotal Myasthenia Study

The European biotech argenx has reported positive top-line results for its FcRn antagonist efgartigimod in generalized myasthenia gravis in the Phase III ADAPT study, and is planning to market the product itself in the US, Japan and major EU countries.

Clinical Trials Neurology

Market Brief: Sales Of Patches To Treat Neurological Disorders Will See Fastest Growth In Global Transdermal Patch Market

The overall transdermal patch market is expected to grow at a CAGR of 2.4% by 2024. Patches to treat neurological disorders will see the fastest growth while pain-management patches will see the most sales.

Market Intelligence Innovation

30 Rising Leaders In The Life Sciences

Revealed: In Vivo’s list of 30 Rising Leaders across the biopharma, medtech and health technology sectors. Find out who made the cut. 

Business Strategies Commercial

Advanz Gets European Heft, Portfolio Assets In Correvio Buyout

Deal Snapshot: Building portfolio and commercial infrastructure in Europe, Advanz gets both at a modest price in acquiring Correvio.

M & A Business Strategies
See All

Company Information

UsernamePublicRestriction

Register